1
|
Rishi P, Verma A, Akhtar Z, Agrawal R, Agrawal A, Kalluri Bharat RP, Rishi E. Intravitreal Ozurdex has no short term influence on choroidal thickness and vascularity index in eyes with diabetic macular edema: A pilot study. Oman J Ophthalmol 2021; 14:179-183. [PMID: 34880580 PMCID: PMC8597814 DOI: 10.4103/ojo.ojo_7_21] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2021] [Revised: 05/08/2021] [Accepted: 06/21/2021] [Indexed: 12/21/2022] Open
Abstract
AIM: To analyze choroidal parameters in eyes with diabetic macular edema (DME) treated with intravitreal Ozurdex. PATIENTS AND METHODS: Twenty eyes of 14 patients were included in this prospective study. Optical coherence tomography images were obtained before and 8–10 weeks after intravitreal Ozurdex injection; binarized and subfoveal choroidal thickness (SFCT) and choroidal vascularity index (CVI) were calculated. RESULTS: Mean SFCT (treatment naïve; 242.22 ± 32.87 reduced to 218.10 ± 22.10, P = 0.158 and previously treated; 330.4 ± 56.72 reduced to 328.93 ± 50.55, P = 0.833) and mean CVI (treatment naïve; 0.64 ± 0.03 changed to 0.65 ± 0.04, P = 0.583 and previously treated; 0.65 ± 0.05 reduced to 0.64 ± 0.03, P = 0.208) showed no significant change. CONCLUSION: Intravitreal Ozurdex showed no significant effects on SFCT and CVI in eyes with DME over short term. Larger studies with longer follow-up may allow a better understanding.
Collapse
Affiliation(s)
- Pukhraj Rishi
- Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralya, Chennai, Tamil Nadu, India
| | - Aditya Verma
- Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralya, Chennai, Tamil Nadu, India
| | - Zeeshan Akhtar
- Elite School of Optometry, Medical Research Foundation, Sankara Nethralaya, Chennai, Tamil Nadu, India.,Srimati Sundari Subramanian Department of Visual Psychophysics, Sankara Nethralya, Chennai, Tamil Nadu, India
| | - Rupesh Agrawal
- National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore.,School of Material Science and Engineering, Nanyang Technological University, Singapore
| | - Ashutosh Agrawal
- Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralya, Chennai, Tamil Nadu, India
| | | | - Ekta Rishi
- Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralya, Chennai, Tamil Nadu, India
| |
Collapse
|
2
|
Majstruk L, Qu-Knafo L, Sarda V, Fajnkuchen F, Nghiem-Buffet S, Grenet T, Chaine G, Giocanti-Auregan A. [Dexamethasone intravitreal implant (Ozurdex) in patients with diabetic macular edema: Real life safety and efficacy]. J Fr Ophtalmol 2020; 43:197-204. [PMID: 32000989 DOI: 10.1016/j.jfo.2019.08.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2018] [Revised: 07/29/2019] [Accepted: 08/20/2019] [Indexed: 01/06/2023]
Abstract
PURPOSE The goal of this study was to investigate the safety and efficacy of the intravitreal dexamethasone implant (DI) for patients with diabetic macular edema (DME) in real life. METHODS We conducted a monocentric retrospective analysis of the change in visual acuity and central macular thickness (CMT) after intravitreal injection of the DI at peak efficacy (2 months after injection) as well as the timing of reinjections and complications in patients with a loss of vision due to DME. RESULTS Forty eyes of 33 patients were included, with a mean follow-up of 12.6 months. Thirty percent of the eyes experienced an increase in best corrected visual acuity (BCVA)>15 letters at peak efficacy (P<0.05) after each ID injection. Treatment-naive patients had a sustained response after Ozurdex injection, with better visual acuity at 3 months (P=0.02) and 4 months (P=0.04) than non-naïve patients and better visual acuity at 6 months despite identical baseline visual acuity (P<0.05). Anatomical efficacy was good, with approximately 60% of patients with CMT<300 microns at peak efficacy after each injection of ID. Thirty percent of eyes demonstrated ocular hypertension (OHT)>25mmHg at peak efficacy, and 12.5% of eyes required cataract surgery during follow-up. CONCLUSION The DI has good functional and anatomic efficacy in these patients, with a good safety profile. Treatment-naïve patients with more recent DME had a more sustained increase in visual acuity after the injections and better visual recovery at 6 months. This encourages us to initiate DI therapy early if there is no response to anti-vascular endothelial growth factor (anti-VEGF) treatment.
Collapse
Affiliation(s)
- L Majstruk
- Ophthalmology department, Avicenne hospital, DHU Vision and Handicaps, Paris XIII university, 125, rue de Stalingrad, 93000 Bobigny, France
| | - L Qu-Knafo
- Ophthalmology department, Avicenne hospital, DHU Vision and Handicaps, Paris XIII university, 125, rue de Stalingrad, 93000 Bobigny, France
| | - V Sarda
- Ophthalmology department, Avicenne hospital, DHU Vision and Handicaps, Paris XIII university, 125, rue de Stalingrad, 93000 Bobigny, France
| | - F Fajnkuchen
- Ophthalmology department, Avicenne hospital, DHU Vision and Handicaps, Paris XIII university, 125, rue de Stalingrad, 93000 Bobigny, France
| | - S Nghiem-Buffet
- Ophthalmology department, Avicenne hospital, DHU Vision and Handicaps, Paris XIII university, 125, rue de Stalingrad, 93000 Bobigny, France
| | - T Grenet
- Ophthalmology department, Avicenne hospital, DHU Vision and Handicaps, Paris XIII university, 125, rue de Stalingrad, 93000 Bobigny, France
| | - G Chaine
- Ophthalmology department, Avicenne hospital, DHU Vision and Handicaps, Paris XIII university, 125, rue de Stalingrad, 93000 Bobigny, France
| | - A Giocanti-Auregan
- Ophthalmology department, Avicenne hospital, DHU Vision and Handicaps, Paris XIII university, 125, rue de Stalingrad, 93000 Bobigny, France.
| |
Collapse
|
3
|
Sharma A, Kuppermann BD, Bandello F, Lanzetta P, Zur D, Park SW, Yu HG, Saravanan VR, Zacharias LC, Barreira AK, Iglicki M, Miassi F, Veritti D, Tsao S, Makam D, Jain N, Loewenstein A. Intraocular pressure (IOP) after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations-GEODEX-IOP study. Eye (Lond) 2019; 34:1063-1068. [PMID: 31570814 DOI: 10.1038/s41433-019-0616-7] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2019] [Revised: 06/29/2019] [Accepted: 07/31/2019] [Indexed: 11/09/2022] Open
Abstract
PURPOSE To analyse the intraocular pressure rise after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations. METHODS The medical charts of 294 dexamethasone implants between February 2011 and 2017 were reviewed retrospectively. South Asian (India), White (Europe, US and Israel) Latino (Argentina and Brazil) patient data was included in the study. Ocular hypertension (OHT) was defined as intraocular pressure of >25 mmHg or an increase of at least 10 mmHg from baseline. The main indications for treatment were diabetic macular edema (ME) (65.6%), retinal vein occlusion (26.5%), uveitis (7.8%). RESULTS Amongst 294 intravitreal implants, ocular hypertension (>25 mmHg) was recorded in 0, 8 and 9.5% in White, Latino, and South Asian groups, respectively. However, IOP > 20 mmHg was recorded in 14%, 28% and 27% in White, Latino, and South Asian groups, respectively. Incidence of very high IOP (>35 mmHg) was lower in all geographical groups. It was 3% in Latino followed by 2% in South Asian group. CONCLUSION Latino and South Asian groups have higher IOP rise compared to White population. Most patients with elevated IOP fluctuate between 20-25 mmHg.
Collapse
Affiliation(s)
- Ashish Sharma
- Lotus Eye Hospital and Institute, Avinashi Road, Coimbatore, TN, India.
| | - Baruch D Kuppermann
- Gavin Herbert Eye Institute at the University of California, Irvine, CA, USA
| | - Francesco Bandello
- University Vita-Salute, Scientific Institute San Raffaele, Milano, Italy
| | - Paolo Lanzetta
- Department of Ophthalmology, University of Udine, Udine, Italy
| | - Dinah Zur
- Division of Ophthalmology, Tel Aviv Sourasky Medical Center And Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Sung Wook Park
- Department of Ophthalmology, Seoul National University Hospital, Seoul, 03080, Republic of Korea.,Seran Eye Center, Seoul, 06167, Republic of Korea
| | - Hyeong Gon Yu
- Department of Ophthalmology, Seoul National University Hospital, Seoul, 03080, Republic of Korea
| | - V R Saravanan
- Department of Vitreoretina, Aravind Eye Hospital, Coimbatore, TN, India
| | - Leandro Cabral Zacharias
- University of Sao Paulo Medical School Allan Kardec Barreira: Attending- University of Sao Paulo; Medical Director- HCLOE Eye Hospital, Sao Paulo, Brazil
| | - Alan K Barreira
- University of Sao Paulo Medical School Allan Kardec Barreira: Attending- University of Sao Paulo; Medical Director- HCLOE Eye Hospital, Sao Paulo, Brazil
| | - Matias Iglicki
- Private Retina Service. University of Buenos Aires, Buenos Aires, Argentina
| | | | - Daniele Veritti
- Department of Ophthalmology, University of Udine, Udine, Italy
| | - Sean Tsao
- Gavin Herbert Eye Institute at the University of California, Irvine, CA, USA
| | - Deepika Makam
- Lotus Eye Hospital and Institute, Avinashi Road, Coimbatore, TN, India
| | - Nidhee Jain
- Department of Vitreoretina, Aravind Eye Hospital, Coimbatore, TN, India
| | - Anat Loewenstein
- Division of Ophthalmology, Tel Aviv Sourasky Medical Center And Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|